An Open-Label, Randomized, Controlled Phase 3 Study of Sigvotatug Vedotin in Combination with Pembrolizumab Compared with Pembrolizumab Monotherapy as First-Line Treatment in Participants with PD-L1 High (≥50% of Tumor Cells Expressing PD-L1), Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer (Be6A Lung-0
